#aGVHD
LightNews LightNews
hemedoc.bsky.social
#tandem25 #bmtsm Maas-Bauer: ROCK1/2 inhibition and JAK inhibition have synergistic effects (!). Belumosudil has yet to be studied clinically in SR-aGVHD.
February 12, 2025 at 9:29 PM
jmaakaron.bsky.social
ash.confex.com/ash/2024/web...

GLP-2 agonist for treatment of aGVHD. 31 patients, mostly with G 3/4 GVHD. ORR ~50% with durable CRs of ~30%. 11 patients with G5 events - unrelated to study drug. Unmet need for non-immunosuppressive therapies
#ASH24
#BMTsm
Paper: Safety and Efficacy of the Glucagon-like Peptide 2 (GLP-2) Analog Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-Versus-Host Disease (aGvHD) in Combination with Be...
ash.confex.com
December 3, 2024 at 3:45 AM
hemedoc.bsky.social
#tandem25 #bmtsm Boiko: Macrophages not all bad and certainly not dispensable. Eg, CSF1R inhibition early after allograft in mouse model accelerates aGVHD pathogenesis.
February 13, 2025 at 9:30 PM
hemedoc.bsky.social
#tandem25 #bmtsm Arnhold: in vivo, corticosteroids protect (prophylactiay given) from gut GVHD; however, when given after onset of aGVHD, steroids don’t work in this mouse model. Steroids associated with decreased epithelial regeneration in aGVHD.
February 12, 2025 at 9:07 PM
silasinman.bsky.social
FDA Approves Remestemcel-L in Pediatric SR-aGVHD www.cancernetwork.com/view/fda-app...
FDA Approves Remestemcel-L in Pediatric SR-aGVHD
Data from the phase 3 MSB-GVHD001 trial support the FDA approval of rememstemcel-L in pediatric SR-aGVHD.
www.cancernetwork.com
December 19, 2024 at 12:15 PM
hemedoc.bsky.social
#tandem25 #bmtsm Arnhold: we aren’t at the point where we can abandon steroids in aGVHD, but it’s as clear as ever that that needs to be a high priority for innovation in GVHD care.
February 12, 2025 at 9:15 PM
hemedoc.bsky.social
#tandem25 #bmtsm Maas-Bauer: ROCK1 (isoform of ROCK2, target of Belumosudil) is most differentially upregulated kinase in non-responders to aGVHD therapy. ROCK1/2 inhibition reduces aGVHD in mouse model of major MHC mismatch allo. Assoc w reduction of CD11b+ cells in gut.
February 12, 2025 at 9:20 PM
hemedoc.bsky.social
#tandem25 #bmtsm Maas-Bauer: ROCK1/2 inhibition of monocyte/macrophage and DCs ameliorates aGVHD, but does not (completely) antagonize tumor cell killing (in vitro and in vivo models).
February 12, 2025 at 9:27 PM
medicine.stitches.today
A double-dose anti-CD25 monoclonal antibody successfully replaces methotrexate, reducing severe aGVHD in haplo-HSCT patients.

by Zhang A, Huang Z (...) Hu Y et 7 al. in Br J Haematol #MedSky

📖 read the article: https://onlinelibrary.wiley.com/doi/10.1111/bjh.19958
December 31, 2024 at 10:32 AM
hemedoc.bsky.social
#tandem25 #bmtsm Gandhi: aGVHD mgmt remains principally managed by steroids in 1L but the use of risk stratification using MAGIC criteria enables studies to use less/no steroids in lower risk aGVHD.
February 15, 2025 at 11:05 PM
bild.bsky.social
Bu alt grubun tedaviyi de yönlendirebileceğini test etmek için ekip, aGVHD tanısı konmuş 20 hastayı daha ayrıntılı olarak analiz etti.
January 18, 2026 at 6:06 PM
hemedoc.bsky.social
#tandem25 #bmtsm Gandhi: Remestemcel MSC in SR-aGVHD show 70% ORR at d28. Approved now for Peds (but not adult pts, so a CTN study is coming to address this).
February 15, 2025 at 11:14 PM
eurofinsviracor.bsky.social
Visit us at #ASH2023 in booth 📍 3405 and learn more about our diagnostic methods to predict outcomes for aGVHD.

🔽 Download the white paper by Steve Kleiboeker, PhD.
www.eurofins-viracor.com/clinical/our...

#ASH23 #aGVHD #GVHD #HCT
December 6, 2023 at 4:19 PM
hemedoc.bsky.social
#tandem25 #bmtsm Gandhi: A1AT studied as therapy in HR-aGVHD. Data to be presented during LBA sesh today.
February 15, 2025 at 11:06 PM
hemedoc.bsky.social
#ASH24 #bmtsm Popat: 2yr relapse 16%, NRM 22%. aGVHD gr3+ 14%, mod+ cGVHD 8% at 24mos. No diff in RFS/OS for younger vs older pts. All pts had AML or hrMDS amongst whom TP53m relapse rate was 36.4% vs 10.5% in TP53wt.
December 8, 2024 at 6:09 PM
maatpharma.bsky.social
📢 [EVENT] – Join Guilhaume Deboras, Head of Corporate Development of MaaT Pharma, at the 10th Annual @Microbiome Movement Summit Europe, taking place on January 28-29 in London, UK.

👉 Learn more: microbiome-europe.com

#Microbiome #aGvHD #Oncology #Hematology #Innovation #Xervyteg
January 15, 2026 at 3:55 PM
bild.bsky.social
Transplantasyon sonrası ilk ay içinde periferik kanda bu hücrelerin oranı %36,6'nın üzerine çıktığında, bu durum sonraki aGVHD için oldukça doğru bir erken uyarı sinyali olarak işlev gördü.
January 18, 2026 at 6:05 PM
eurofinsviracor.bsky.social
🧪 It's Lab Week 2025! | DAY 1
We’re solving cases from pre- & post-transplant testing to rare infections & immune conditions.

First up is our aGVHD Algorithms.

🥼 aGVHD: www.eurofins-viracor.com/our-testing/...

#LabWeek2025 #aGVHD #MysteryMachineofDiagnostics #LabLife #CelebrateLabWeek
April 20, 2025 at 10:22 AM
hemedoc.bsky.social
#tandem25 #bmtsm Gandhi: Ruxolitinib is preferred therapy for SR-aGVHD based on REACH1+2 studies. Rux Day 28 ORR 62%, 40% at d56 in REACH 2.
February 15, 2025 at 11:12 PM
eurofinsviracor.bsky.social
🧪 NEW ASSAY!
Manhattan Plus MAGIC aGVHD Composite Risk Analysis Assay.
READ 👉 www.eurofins-viracor.com/test-menu/40...

Better stratification & analysis of symptomatic aGVHD risks with NEW Manhattan scoring algorithm inclusion.
• Improved prognostic performance(6mo non-relapse mortality) #agvhd #bmt
February 10, 2025 at 8:01 PM
asgct.bsky.social
Yesterday, #Ryoncil became the first FDA-approved mesenchymal stromal #celltherapy indicated to treat steroid-refractory acute graft-versus-host disease (SR-aGVHD) in patients who are two months and older. #stemcells www.fda.gov/news-events/...
FDA Approves First Mesenchymal Stromal Cell Therapy to Treat Steroid-refractory Acute Graft-versus-host Disease
FDA approves Ryoncil, the first MSC therapy to treat steroid-refractory acute graft-versus-host disease (SR-a GVHD) in pediatric patients 2 months of age and ol
www.fda.gov
December 19, 2024 at 6:32 PM
leeat-keren.bsky.social
Paper alert! A spatial atlas of human gastrointestinal acute GVHD reveals epithelial and immune dynamics underlying disease pathophysiology. We examined how immune cells are organized in the gut and what happens to them in GVHD. TL;DR Timing is key! www.science.org/doi/10.1126/...
A spatial atlas of human gastrointestinal acute GVHD reveals epithelial and immune dynamics underlying disease pathophysiology
Multiplexed imaging of aGVHD GI biopsies revealed epithelial remodeling and alteration in immune composition, offering insight into disease pathology.
www.science.org
November 6, 2025 at 5:51 AM
hemedoc.bsky.social
#tandem25 #bmtsm Salhotra: opportunities to improve GVHD ppx include adding mAbs or targeted signaling inhibitors to CNI/MTX, use of PTCy, and/or graft manipulation. Abatacept is for MMUD assoc with less aGVHD.
February 15, 2025 at 10:47 PM
karenenglish.bsky.social
Fantastic to see Mesoblast's MSC cell therapy product finally approved for pediatric aGVHD.

www.globenewswire.com/news-release...
Mesoblast’s RYONCIL® is the First U.S. FDA-Approved Mesenchymal Stromal Cell (MSC) Therapy
RYONCIL (remestemcel-L) is the first MSC product approved by FDA for any indication.RYONCIL is the first FDA-approved therapy for children aged 2 months...
www.globenewswire.com
December 19, 2024 at 8:08 AM
maatpharma.bsky.social
📄[Press release] – MaaT Pharma Receives Positive Opinion from EMA Pediatric Committee on the Pediatric Investigation Plan for MaaT013 for the treatment of acute Graft-versus-Host Disease🩸
See the press release: maatpharma.com/march-11-202...

#Cancer #EMA #aGvHD #Pediatric #EMA #Milestone
March 11, 2025 at 5:35 PM